Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia

Journal of Clinical Microbiology

Volumn 41, Issue 10, 2003, Pages 4898-4900

  Durand Joly, Isabelle ^a,c   Alfandari, Serge ^d   Benchikh, Zinnédine ^a   Rodrigue, Marion ^a   Espinel Ingroff, Ana ^e   Catteau, Benoit ^b   Cordevant, Christophe ^c   Camus, Daniel ^a,c   Dei Cas, Eduardo ^a,c   Bauters, Francis ^b   Delhaes, Laurence ^a,c   De Botton, Stéphane ^b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d Service des Maladies Infectieuses   (France)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CEFEPIME; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VORICONAZOLE;

ACUTE LEUKEMIA; ADULT; ARTICLE; BLOOD CULTURE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; FEVER; FUSARIUM OXYSPORUM; HUMAN; HUMAN TISSUE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SKIN BIOPSY; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DERMATOMYCOSES; DRUG THERAPY, COMBINATION; FEMALE; FUSARIUM; HUMANS; LEUKEMIA, B-CELL, ACUTE; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

FUSARIUM; FUSARIUM OXYSPORUM;

EID: 10744225192     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.10.4898-4900.2003     Document Type: Article

References (16)

1. Anaissie, E., H. Kantarjian, P. Jones, B. Barlogie, M. Luna, G. Lopez-Berestein, and G. P. Bodey. 1986. Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer 57:2141-2145.
2. Arikan, S., M. Lozano-Chiu, V. Paetznick, S. Nangia, and J. H. Rex. 1999. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol. 37:3946-39451.
3. Boutati, E. I., and E. J. Anaissie. 1997. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 90:999-1008.
4. Dei-Cas, E., L. Dujardin, M. E. Ribeiro Pinto, F. Ajana, J. Fruit, D. Poulain, D. Camus, and A. Vernes. 1991. Kinetic study of antifungal activity of amphotericin B, 5-fluorocytosine and ketoconazole against clinical yeast isolates using liquid-phase turbidimetry. Mycoses 34:167-172.
5. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
6. Espinel-Ingroff, A., K. Boyle, and D. J. Sheehan. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115.
7. Girmenia, C., A. P. Iori, F. Boecklin, A. Torosantucci, P. Chiani, P. De Fabritiis, F. Taglietti, A. Cassone, and P. Martino. 1999. Fusarium infections in patients with severe aplastic anemia: review and implications for management. Haematologica 84:114-118.
8. Guarro, J., and J. Gene. 1995. Opportunistic fusarial infections in humans. Eur. J. Clin. Microbiol. Infect. Dis. 14:741-754.
9. Hennequin, C., V. Lavarde, J. L. Poirot, M. Rabodonirina, A. Datry, S. Aractingi, J. Dupouy-Camet, D. Caillot, F. Grange, L. Kures, O. Morin, B. Lebeau, S. Bretagne, C. Guigen, D. Basset, and R. Grillot. 1997. Invasive Fusanum infections: a retrospective survey of 31 cases. The French 'Groupe d'Etudes des Mycoses Opportunistes' GEMO. J. Med. Vet. Mycol. 35:107-114.
10. Hoffman, H. L., and R. C. Ratbbun. 2002. Review of the safety and efficacy of voriconazole. Expert Opin. Investig. Drugs 11:409-429.
11. Letscher-Bru, V., F. Campos, J. Waller, R. Randriamahazaka, E. Candolfi, and R. Herbrecht. 2002. Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient. J. Clin. Microbiol. 40:1100-1102.
12. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, vol. 22. Approved standard M-38A. NCCLS, Wayne, Pa.
13. Okada, H., S. Hamatani, M. Kondo, T. Imai, S. Itoh, K. Isobe, and S. Onishi. 2000. Successful treatment of disseminated Fusarium infection in an infant with leukemia. Int. J. Hematol. 72:494-498.
14. Pagano, L., C. Girmenia, L. Mele, P. Ricci, M. E. Tosti, A. Nosari, M. Buelli, M. Picardi, B. Allione, L. Corvatta, D. D'Antonio, M. Montillo, L. Melillo, A. Chierichini, A. Cenacchi, A. Tonso, L. Cudillo, A. Candoni, C. Savignano, A. Bonini, P. Martino, and A. Del Favero. 2001. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 86:862-870.
15. Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
16. Reis, A., R. Sundmacher, K. Tintelnot, H. Agostini, H. E. Jensen, and C. Althaus. 2000. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br. J. Ophthalmol. 84:932-933.